Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATF4 | P18848 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090052 | 0.87 | — | — | |
| SCHEMBL10281501 | 0.83 | NPSR1 (0.42) | NPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL23081204 | 0.82 | NPSR1 (0.63) | NPSR1KMT2AMEN1ALDH1A1KDM5A | |
| SCHEMBL25444121 | 0.82 | NPSR1 (0.63) | NPSR1KMT2AMEN1ALDH1A1KDM5A | |
| SCHEMBL25444138 | 0.82 | NPSR1 (0.63) | NPSR1KMT2AMEN1ALDH1A1KDM5A | |
| SCHEMBL13130101 | 0.80 | NPSR1 (0.70) | NPSR1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL15247292 | 0.80 | SMN1; SMN2 (0.38) | NPSR1KMT2AALDH1A1LMNASMN1; SMN2 | |
| Carbamic Acid SCHEMBL11200157 | 0.80 | NPSR1 (0.70) | NPSR1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL22651967 | 0.80 | NPSR1 (0.70) | NPSR1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL14492244 | 0.80 | NPSR1 (0.70) | NPSR1KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | NPSR1 2720/4885KMT2A 1997/4885MEN1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.